(VIANEWS) – Shares of Exact Sciences (NASDAQ: EXAS) rose by a staggering 30.01% in 21 sessions from $62.68 at 2023-04-26, to $81.49 at 15:54 EST on Thursday, following the last session’s upward trend. NASDAQ is jumping 1.76% to $12,704.26, after two sequential sessions in a row of losses.
Exact Sciences’s last close was $82.50, 1.47% below its 52-week high of $83.73.
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Earnings Per Share
As for profitability, Exact Sciences has a trailing twelve months EPS of $-2.94.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.36%.
Moving Average
Exact Sciences’s value is way above its 50-day moving average of $67.91 and way above its 200-day moving average of $52.46.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Exact Sciences’s EBITDA is 7.34.
More news about Exact Sciences (EXAS).
